论文部分内容阅读
如果未经许可,仿制国外专利药品,药厂将面临被索赔4亿到10亿美元的赔偿费。加入世贸组织后,对于国外处于专利保护期、且在我国申请了专利或者行政保护的新药,我国的药品生产企业将不得擅自仿制。据介绍,外国公司没有来中国申请保护的专利中,尤其是制备方法专利、生化专利、制剂专利、用途专利等,我国医药生产企业可以无偿使用。但仿制产品出口时,需了解所到国家的专利状况。如该专利已在所到国
If imitation of foreign patented drugs without permission, pharmaceutical companies will face claims for compensation of 400 million to 1 billion US dollars. After joining the WTO, pharmaceutical manufacturing enterprises in China will not be allowed to copy the new drugs that are patent-protected abroad and have applied for patent or administrative protection in China. According to reports, foreign companies do not come to China to apply for protection of patents, especially preparation method patents, biochemical patents, preparation patents, use patents, etc., China’s pharmaceutical production enterprises can use free of charge. However, when exporting imitation products, it is necessary to understand the patent status of the country. If the patent is already in the country